Introduction Self-management skills can help patients with Parkinson’s disease to adopt healthy behaviors and live well, thereby improving outcomes and reducing costs. Methods Patients with parkinsoni...

Parkinsonism is not a diagnosis, but rather a term used to describe a set of symptoms. These symptoms include stiffness (rigidity), slowness of movement (bradykinesia), and shaking body parts (often r...

Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by dopaminergic neuron loss and α-synuclein aggregation. Epigenetic mechanisms, including mitochondrial DNA (mtDNA...

Wei et al. show that SNCA-A53T transgenic monkeys recapitulate the natural progression of Parkinson’s disease. The animals display REM sleep behaviour diso

Orthostatic hypotension (OH) is a frequent autonomic feature of Parkinson's disease (PD), yet its long-term clinical consequences remain insufficiently characterized, particularly regarding falls and ...

Linear GBCAs marginally increase the risk of parkinsonism in adults, but exposure to macrocyclic GBCAs doesn't appear to.

Background: Drug-induced parkinsonism (DIP) predominantly occurs due to antipsychotic drugs (APDs) blocking dopamine D2 receptors (D2R). However, in vitro assays often fail to fully reflect real-world variability in clinical outcomes. Objective: This study aimed to evaluate whether in vitro pharmacological metrics correspond to real-world risk of DIP associated with APD use. Methods: For eight commonly used APDs, key in vitro parameters—including inhibition constants (Ki) of D2R and serotonin 2A receptor, reversal rate (Kr) of D2R, and blood-brain barrier penetration rate (BBBpr)—were compiled to construct six composite DIP risk metrics. The real-world DIP risk was assessed using the Seoul National University Hospital Common Data Model (2002–2021). APD users were matched 1:1 to selective serotonin reuptake inhibitor users using propensity score matching, and Cox proportional hazards regression was performed to estimate the hazard ratios (HRs) for DIP risk. Correlation between each in vitro metric and real-world DIP risk was evaluated using logarithmic regression models. Results: Among 44,664 patients from eight matched cohorts, haloperidol showed the highest DIP risk (HR 4.56; 95% confidence interval [CI], 2.29–9.07), whereas aripiprazole exhibited the lowest risk (HR 2.11; 95% CI, 1.56–2.86). Metric 4 (pKr × BBBpr) demonstrated the strongest correlation with real-world DIP risk (R2=0.95). The correlation decreased when aripiprazole, a partial D2R agonist, was included in the analysis (R2=0.58). Conclusions: Integrating receptor-binding kinetics with BBB penetration may provide an in vitro framework that reflects real-world variation in DIP risk among D2R-antagonizing APDs. These findings support the relevance of combining kinetic and central nervous system exposure parameters for early safety evaluation.